Complementary and alternative medicine use for vasomotor symptoms among women who have discontinued hormone therapy

JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing

Volumn 38, Issue 1, 2009, Pages 50-59

  Kupferer, Elizabeth M ^a,c   Dormire, Sharon L ^b   Becker, Heather ^b  

^a Duramed Research Inc   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c NONE   (United States)

Author keywords

Casomotor symptoms; Complementary and alternative medicine systems; Menopause

Indexed keywords

EID: 58849114069     PISSN: 08842175     EISSN: 15526909     Source Type: Journal    
DOI: 10.1111/j.1552-6909.2008.00305.x     Document Type: Article

References (34)

1. Adlecreutz, H., Hämäläinen, E., Gorbach, S., & Golden, B. (1992). Dietary phytoestrogens and the menopause in Japan. Lancet, 339, 1233.
2. Amato, P., Christophe, S., & Mellon, P. L. (2002). Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause, 9(2), 145-150.
3. Bair, Y. A., Gold, E. B., Azari, R. A., Greendale, G., Sternfeld, B., Harkey, M. R., et al. (2005). Use of conventional and complementary health care during the transition of menopause: Longitudinal results from the Study of Women's Health Across the Nation (SWAN). Menopause: The Journal of the North American Menopause Society, 12(1), 31-39.
4. Bair, Y. A., Gold, E. B., Greendale, G. A., Sternfeld, B., Adler, S. R., Azari, R., et al. (2002). Ethnic differences in use of complementary and alternative medicine at midlife: Longitudinal results from SWAN participants. American Journal of Public Health, 92(11), 1832-1840.
5. Bair, Y. A., Gold, E. B., Zhang, G., Rasor, N., Utts, J., Upchurch, D., et al. (2008). Use of complementary and alternative medicine during the menopause transition: Longitudinal results from the Study of Women's Health Across the Nation. Menopause: The Journal of the North American Menopause Society, 15(1), 32-43.
6. Barber, C. A., Margolis, K., Luepker, R. V., & Arnett, D. K. (2004). The impact of the women's health initiative on discontinuation of postmenopausal hormone therapy: The Minnesota Heart Survey (2000-2002). Journal of Women's Health, 13(9), 975-985.
7. Berendsen, H. H. (2000). The role of serotonin in hot flushes. Maturitas, 36(3), 155-164.
8. Bestul, M. B., McCollum, M., Hansen, L. B., & Saseen, J. J. (2004). Impact of the Women's Health Initiative Trial results on hormone replacement therapy. Pharmacotherapy, 24(4), 495-499.
9. Blümel, J. E., Castelo-Branco, C., Chedraui, P. A., Binfa, L., Dowlani, B., Soledad-Gómez, M., et al. (2004). Patients' and clinicians' attitudes after Women's Health Initiative Study. Menopause: The Journal of the North American Menopause Society, 11(1), 57-61.
10. Buist, D. S. M., Newton, K. M., Miglioretti, D. L., Beverly, K., Connelly, M. T., & Andrade, S. (2004). Hormone therapy prescribing patterns in the United States. Obstetrics and Gynecology, 104(5, Pt. 1), 1042-1050.
11. Factor-Litvak, P., Cushman, L. F., Kronenberg, F., Wade, C., & Kalmuss, D. (2001). Use of complementary and alternative medicine among women in New York City: A pilot study. Journal of Alternative and Complementary Medicine, 7(6), 659-666.
12. Gold, E. B., Bair, Y., Zhang, G., Utts, J., Greendale, G. A., Upchurch, D., et al. (2007). Cross-sectional analysis of specific complementary and alternative medicine (CAM) use by racial/ethnic group and menopausal status: The Study of Women's Health Across the Nation (SWAN). Menopause: The Journal of the North American Menopause Society, 14(4), 612-623.
13. Gonzales, G. F., & Carillo, C. (1993). Blood serotonin levels in postmenopausal women: Effects of age and serum estradiol. Maturitas, 17, 23-29.
14. Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., et al. [HERS Research Group]. (2002). Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). Journal of the American Medical Association, 288(1), 58-66.
15. Hersh, A. L., Stefanick, M. L., & Stafford, R. S. (2004). National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. Journal of the American Medical Association, 291(1), 47-53.
16. Hillman, J. J., Zuckerman, I. H., & Lee, E. (2004). The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program. Journal of Women's Health, 13(9), 986-992.
17. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., et al. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS). Journal of the American Medical Association, 280(7), 605-613.
18. Kam, I. W., Dennehy, C. E., & Tsourounis, C. (2002). Dietary supplement use among menopausal women attending a San Francisco health conference. Menopause, 9(1), 72-78.
19. Kaufert, P., Boggs, P. P., Ettinger, B., Woods, N. F., & Utian, W. H. (1998). Women and menopause: Beliefs, attitudes, and behaviors. The North American Menopause Society 1997 Menopause Survey. Menopause, 5(4), 197-202.
20. Kronenberg, F., Cushman, L. F., Wade, C. M., Kalmuss, D., & Chao, M. T. (2006). Race/ethnicity and women's use of complimentary and alternative medicine in the United States: Results of a national survey. American Journal of Public Health, 96(7), 1236-1242.
21. Kronenberg, F., & Fugh-Berman, A. (2002). Review of complementary treatments for menopause. Annals of Internal Medicine, 137(10), 805-813.
22. Nagata, C., Shimizu, H., Takami, R., Hayashi, M., Takeda, N., & Yasuda, K. (1999). Hot flushes and other menopausal symptoms in relation to soy product intake in Japanese women. Climacteric, 2(1), 6-12.
23. Nagata, C., Takatsuka, N., Kawakami, N., & Shimizu, H. (2001). Soy product intake and hot flashes in Japanese women: Results from a community-based prospective study. American Journal of Epidemiology, 153(8), 790-793.
24. National Center for Complementary and Alternative Medicine. (2005). Get the Facts. Retrieved on September 4, 2005, from http://nccam.nih.gov/ health/whatiscam/#1
25. National Institute of Health. (2005). State-of-the-Science Conference Statement on management of menopause-related symptoms. NIH Consensus and State-of-The-Science Statements, 22(1), 1-38.
26. Newton, K. M., Buist, D. S. M., Keenan, N. L., Anderson, L. A., & LaCroix, A. Z. (2002). Use of alternative therapies for menopause symptoms: Results of a population based survey. Obstetrics and Gynecology, 100(1), 18-25.
27. North American Menopause Society. (2004). Treatment of menopause-associated vasomotor symptoms. Position statement: The North American menopause society. Society Menopause: The Journal of the North American Menopause Society 2004, 11(1), 11-33.
28. Ockene, J.K, Barad, D. H., Cochrane, B. B., Larson, J. C., Gass, M., Wassertheil-Smoller, S., et al. (2005). Symptom experience after discontinuing use of estrogen plus progestin. Journal of the American Medical Association, 294(2), 182-193
29. Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association, 288(3), 321-333.
30. Speroff, L., & Fritz, M. A. (2005). Clinical gynecologic endocrinology and infertility (7th ed.). Baltimore: Lippincott, Williams & Wilkins.
31. U.S. Department of Health and Human Services. (2006). Poverty Guidelines 2006. Federal Register, 71(15), 3848-3849.
32. United States Food and Drug Administration. (2004). FDA news: FDA updates hormone therapy information for postmenopausal women. Retrieved July 17, 2005, from http://www.fda.gov/bbs/topics/NEWS/2004/NEW01022.html
33. Wilkin, J. K. (1981). Flushing reactions: Consequences and mechanisms. Annals of Internal Medicine, 95(4), 468-477.
34. Wysowski, D. K., & Governale, L. A. (2005). Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiology and Drug Safety, 14, 171-176.